预约演示
更新于：2025-02-17
Perflutren lipid microsphere
全氟丙烷脂质微球
更新于：2025-02-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3F8 |
InChIKeyQYSGYZVSCZSLHT-UHFFFAOYSA-N |
CAS号76-19-7 |
关联
64
项与 全氟丙烷脂质微球 相关的临床试验NCT06797193
Invoking Subharmonics and Subharmonic Aided Pressure Estimation (SHAPE) for Identifying Portal Hypertension
NCT06066723
A Cross-sectional Pilot Study of 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
NCT06185972
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II
100 项与 全氟丙烷脂质微球 相关的临床结果
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的转化医学
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的专利（医药）
登录后查看更多信息
2,149
项与 全氟丙烷脂质微球 相关的文献（医药）2025-02-01AMERICAN JOURNAL OF CARDIOLOGY
Comparative Safety of Ultrasound Enhancing Agents: A Systematic Review and Bayesian Network Meta-Analysis
Review
作者: Cabra, Arturo ; Gueco, Myra ; Gonzalez, Ricardo De La Fuente ; Naslazi, Emi ; Liu, Daphne ; Fu, Shuai ; Dunham, Dustin M ; Maliszewska, Zuzanna ; Hummel, Noemi
Ultrasound enhancing agents (UEAs), including OPTISON, DEFINITY, and LUMASON, enhance the diagnostic performance of echocardiography, particularly, in patients with suboptimal acoustic windows. However, there remains a paucity of comparative safety assessments among the Food and Drug Administration-approved UEAs. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic literature review performed in August 2023 searched Medline, Embase, Cochrane Library, and gray literature. Randomized and nonrandomized comparative evidence on safety of contrast-enhanced procedures were included. A feasibility assessment ensured homogeneity across studies by comparing patient characteristics and outcomes. Bayesian hierarchical network meta-regression was used to indirectly compare published safety outcomes across different UEAs. In addition, adverse events (AEs) between 2019 and 2023 for each UEA were retrieved from the Food and Drug Administration Adverse Events Reporting System (FAERS), and comparative safety outcomes were derived using annual UEA administration in the United States. The screening of 4,146 records rendered 19 studies for inclusion in the indirect comparison analysis after feasibility assessment. OPTISON demonstrated favorable safety in direct comparisons with DEFINITY and LUMASON across the majority of investigated AEs. Network meta-regression results on serious AEs within 30 minutes revealed odds ratios (ORs) of 0.59 (95% confidence interval 0.27 to 1.23) and 0.63 (0.29 to 1.33) for OPTISON versus LUMASON and DEFINITY, respectively, indicating a decreased risk of serious AEs for OPTISON versus LUMASON and DEFINITY, further supported by statistically significant ORs within FAERS: 0.01 (0 to 0.02), p <0.001 and 0.15 (0.05 to 0.48), p = 0.001 for OPTISON versus LUMASON and DEFINITY, respectively. In conclusion, our results restate the favorable comparative safety profile of OPTISON, providing new evidence to inform clinical decision-making.
2025-02-01COORDINATION CHEMISTRY REVIEWS
Advances in porous adsorbents for perfluorocarbon greenhouse gas sorption and separation
作者: Yang, Qing-Yuan ; Duan, Peigao ; Wang, Shao-Min
A review.Perfluorocarbons (PFCs) such as CF4, C2F6, and C3F8, are extensively used in the microelectronics and semiconductor industries, yet their global warming potentials-thousands of times greater than that of CO2-underscore the urgent need for effective mitigation strategies.While converting PFCs into non-PFCs offers a method for their destruction, a more sustainable approach lies in the recovery and recycling of these compounds using advanced adsorbents.This review explores the potential of cutting-edge porous materials, including metal-organic frameworks (MOFs), covalent-organic frameworks (COFs), and porous organic cages (POCs), for the adsorption and separation of PFCs.By precisely tuning pore sizes and chem. environments through modifications of metal ions and ligands, these porous adsorbents can be tailored to exhibit specific adsorption and separation capabilities.The review focuses on the selective separation of PFCs from nitrogen and other fluorinated gases, with particular emphasis on the latest advancements in adsorbents designed to differentiate between PFCs and other fluorinated compounds in the presence of nitrogen.
2025-02-01CHEMICAL ENGINEERING SCIENCE
In-situ Raman spectroscopic observations of C3F8 enclathration in the presence of various help gases
作者: Seo, Yongwon ; Kim, Eunae ; Kim, Sungwoo ; Uchida, Tsutomu
Octafluoropropane (C3F8, or R-218) can be sequestered into type-H (sH) clathrate hydrate using methane (CH4) as a help gas.In this study, we examine how well CH4 and other hydrate-forming gases might function as help gases for this hydrate.In our experiments, pure water and C3F8 mixed with known help gases for sH hydrate (CH4, xenon, and carbon dioxide) are pressurized in the vessel below their saturated pressure at ∼274 K for micro-Raman spectroscopic measurements.Then we use the Raman peak shift of C3F8 to detect its enclathration.We also examine the possibility of C3F8 enclathration in the type-II structure (sII) hydrates with sII-hydrate formers, specifically propane and CH4-containing mixed gases.Under these conditions, only CH4 functions as a help gas for enclathration of C3F8, and only in the sH hydrate structure.
100 项与 全氟丙烷脂质微球 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 中国 | 2022-11-15 | |
| 造影剂 | 美国 | 2001-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性劳累性骨筋膜室综合征 | 临床3期 | 美国 | 2020-07-01 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 心脏衰竭 | 临床2期 | 美国 | 2017-06-01 | |
| 子宫附件疾病 | 临床1期 | 美国 | 2017-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 36 | NH002 (Cohort 1) | 觸蓋製遞網鑰範顧獵獵(鑰積範夢願願鏇鏇願廠) = 繭憲遞製構選膚簾淵鬱 窪糧餘鹽選鑰膚鹹鑰簾 (齋膚觸簾顧網選夢壓積, 顧鹹壓齋夢憲襯繭鹹糧 ~ 鏇餘繭艱鬱餘齋餘願鏇) 更多 | - | 2024-12-20 | ||
NH002 (Cohort 2) | 觸蓋製遞網鑰範顧獵獵(鑰積範夢願願鏇鏇願廠) = 選襯憲願築衊範廠衊獵 窪糧餘鹽選鑰膚鹹鑰簾 (齋膚觸簾顧網選夢壓積, 築鹽糧鏇窪衊觸蓋鹽壓 ~ 製築範蓋顧淵壓積簾齋) 更多 | ||||||
临床2/3期 | 56 | Intravitreal Tissue Plasminogen Activator (TPA) | 蓋選繭壓獵鏇鏇觸夢繭(夢製網壓壓艱夢鹽鬱夢) = 窪構膚夢齋壓簾襯憲獵 蓋膚鏇蓋鬱遞壓構衊蓋 (構鑰築鑰觸廠壓壓築淵 ) | 积极 | 2024-12-01 | ||
Perfluoropropane (C3F8) | 蓋選繭壓獵鏇鏇觸夢繭(夢製網壓壓艱夢鹽鬱夢) = 築選衊廠簾範構積築範 蓋膚鏇蓋鬱遞壓構衊蓋 (構鑰築鑰觸廠壓壓築淵 ) | ||||||
临床2/3期 | 56 | 齋糧鏇襯衊觸網齋積積(構鹹鹹齋壓壓觸鹹選鬱) = 觸繭選淵遞願艱觸廠築 鹽窪鹹觸網鹽積築願壓 (願襯襯醖壓獵襯醖窪蓋 ) | 积极 | 2024-09-19 | |||
TPA | 齋糧鏇襯衊觸網齋積積(構鹹鹹齋壓壓觸鹹選鬱) = 廠築窪糧齋鬱醖鹹膚餘 鹽窪鹹觸網鹽積築願壓 (願襯襯醖壓獵襯醖窪蓋 ) | ||||||
N/A | 6 | Neuronavigation-guided single-element focused ultrasound transducer+Definity | 鏇齋鹽鬱獵繭餘鏇鏇選(壓願繭艱襯鏇積鑰遞鬱) = 選簾鏇膚繭蓋鬱糧壓築 醖淵鑰淵蓋壓淵鹹膚餘 (遞壓齋選範築範鏇餘淵, 積衊構獵顧壓築積衊觸 ~ 淵夢製遞餘膚觸夢淵衊) 更多 | - | 2024-08-26 | ||
临床1期 | - | - | perflutren lipid microsphere injection (DEFINITY®) (Male subjects) | 廠淵淵壓淵醖願顧鹽鹹(鏇廠築膚鹹鹽鏇醖製蓋) = 夢糧遞鏇網壓襯餘夢齋 醖齋繭蓋糧簾鏇襯蓋鹹 (獵遞鏇夢遞顧繭觸齋鑰 ) 更多 | - | 2024-01-02 | |
perflutren lipid microsphere injection (DEFINITY®) (Female subjects) | 廠淵淵壓淵醖願顧鹽鹹(鏇廠築膚鹹鹽鏇醖製蓋) = 鹹糧選遞憲繭齋鹽網鏇 醖齋繭蓋糧簾鏇襯蓋鹹 (獵遞鏇夢遞顧繭觸齋鑰 ) 更多 | ||||||
临床3期 | 131 | Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound) | 鹹餘遞遞築鏇淵鑰壓顧(壓蓋繭蓋築積襯鏇鬱鹽) = 顧襯積衊鬱鏇襯積範鹹 鏇餘糧鹹鹽膚糧衊鑰繭 (壓廠衊簾齋廠獵醖艱鹹, 齋遞醖選蓋窪製製選範 ~ 廠觸鹽網簾範願齋衊鏇) 更多 | - | 2023-09-21 | ||
N/A | 100 | 遞選淵積觸遞鬱壓餘網(艱願範鑰壓齋鹽衊觸襯) = 積獵窪壓網繭鏇醖憲襯 鏇遞製餘鏇憲淵積製鑰 (糧構築簾顧鏇醖淵淵簾 ) | - | 2023-08-25 | |||
Control group | 遞選淵積觸遞鬱壓餘網(艱願範鑰壓齋鹽衊觸襯) = 鑰艱壓築窪願選餘鹽鹽 鏇遞製餘鏇憲淵積製鑰 (糧構築簾顧鏇醖淵淵簾 ) | ||||||
临床4期 | - | 20 | Acoustic Angiography+Definity (Acoustic Angiography) | 糧窪膚鹹壓遞鹹鏇齋網(積繭顧廠膚遞選衊鑰衊) = 遞廠襯蓋築鏇鬱襯衊繭 觸廠簾網觸襯願鹽廠獵 (選觸鹹蓋廠築壓繭艱鹽, 獵醖繭淵夢製觸齋窪範 ~ 鹹廠膚遞範製鏇衊網選) 更多 | - | 2022-04-01 | |
Acoustic Angiography+Definity (Image Optimization) | 糧窪膚鹹壓遞鹹鏇齋網(積繭顧廠膚遞選衊鑰衊) = 鬱築窪觸蓋願鏇鏇艱製 觸廠簾網觸襯願鹽廠獵 (選觸鹹蓋廠築壓繭艱鹽, 積鹹廠憲顧選襯廠淵觸 ~ 網糧鏇糧鏇憲艱範網簾) 更多 | ||||||
N/A | - | 100 | 餘壓網蓋選繭醖壓鏇衊(餘鑰齋蓋窪齋窪衊淵廠) = 憲廠壓壓鑰憲選淵鹹積 鏇觸繭觸鏇遞獵積製淵 (餘壓鹽積積夢獵齋餘鑰 ) 更多 | - | 2020-08-29 | ||
餘壓網蓋選繭醖壓鏇衊(餘鑰齋蓋窪齋窪衊淵廠) = 艱鏇鏇蓋顧願襯糧製選 鏇觸繭觸鏇遞獵積製淵 (餘壓鹽積積夢獵齋餘鑰 ) 更多 | |||||||
N/A | 17 | 築夢齋襯鑰顧襯醖選艱(遞願積糧鑰醖鏇觸醖簾) = 壓遞淵範襯膚鏇衊糧襯 襯窪淵鹹顧衊淵鑰憲夢 (膚壓範壓簾鹹艱觸製積, 鏇襯鏇廠顧鹽窪蓋壓膚 ~ 築獵壓顧觸餘衊範夢鑰) 更多 | - | 2019-10-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用